On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
The Wilson Sonsini team that advised the underwriters includes:
Corporate
David Sharon
Victor Nilsson
Steve Bernard
Yang Chu
Carole Rosenberg
Josh Sedgwick
Meg Moloney
Gabriele Forbes Bennett
Richard Fielkow
Rujin Ruan
FDA Regulatory
Eva Yin
Patents and Innovations
Michael Hostetler
Minyoung Shin
For more information, please see Legend Biotech’s news release.
